Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Rheumatoid arthritis-associated bronchiectasis - Authors' reply.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2019 May 18;393(10185):2036. doi: 10.1016/S0140-6736(19)30012-1. No abstract available.

PMID:
31106746
2.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

Clin Infect Dis. 2019 May 6. pii: ciz364. doi: 10.1093/cid/ciz364. [Epub ahead of print]

PMID:
31056660
3.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
4.

The study of CFTR modulators in the very young.

Flume PA.

Lancet Respir Med. 2019 Apr;7(4):287-289. doi: 10.1016/S2213-2600(18)30503-4. Epub 2019 Jan 24. No abstract available.

PMID:
30686766
5.

JCF - progress in 2018.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2019 Jan;18(1):1-5. doi: 10.1016/j.jcf.2018.12.008. No abstract available.

PMID:
30665544
6.

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.

Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N.

Ann Am Thorac Soc. 2019 May;16(5):534-539. doi: 10.1513/AnnalsATS.201812-863OT. No abstract available.

7.

Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.

Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL.

J Cyst Fibros. 2018 Dec 23. pii: S1569-1993(18)30942-1. doi: 10.1016/j.jcf.2018.12.004. [Epub ahead of print]

8.

Antimicrobial resistance in cystic fibrosis: Does it matter?

Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):687-689. doi: 10.1016/j.jcf.2018.08.015. Epub 2018 Sep 27. No abstract available.

PMID:
30270113
9.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
10.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Sep 14. doi: 10.1164/rccm.201807-1318OC. [Epub ahead of print]

PMID:
30216086
11.

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2018 Sep 8;392(10150):880-890. doi: 10.1016/S0140-6736(18)31767-7. Review.

PMID:
30215383
12.

Optimizing outcomes of pulmonary exacerbations in cystic fibrosis.

Szentpetery S, Flume PA.

Curr Opin Pulm Med. 2018 Nov;24(6):606-611. doi: 10.1097/MCP.0000000000000519.

PMID:
30124523
13.

Nontuberculous Mycobacteria in Cystic Fibrosis.

Furukawa BS, Flume PA.

Semin Respir Crit Care Med. 2018 Jun;39(3):383-391. doi: 10.1055/s-0038-1651495. Epub 2018 Aug 2. Review.

PMID:
30071553
14.

Mycobacterial Disease: Evolving Concepts.

Flume PA, Winthrop KL.

Semin Respir Crit Care Med. 2018 Jun;39(3):269. doi: 10.1055/s-0038-1660862. Epub 2018 Aug 2. No abstract available.

PMID:
30071542
15.

Benefits of set length antibiotic treatment for pulmonary exacerbations.

Goss CH, Somayaji R, Flume PA.

Lancet Respir Med. 2018 Aug;6(8):575-577. doi: 10.1016/S2213-2600(18)30267-4. Epub 2018 Jun 27. No abstract available.

PMID:
29960882
16.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

17.

Unmet needs in cystic fibrosis: the next steps in improving outcomes.

West NE, Flume PA.

Expert Rev Respir Med. 2018 Jul;12(7):585-593. doi: 10.1080/17476348.2018.1483723. Epub 2018 Jun 19. Review.

PMID:
29855230
18.

Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.

Jennings MT, Flume PA.

Ann Am Thorac Soc. 2018 Aug;15(8):897-902. doi: 10.1513/AnnalsATS.201802-075FR.

PMID:
29812963
19.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkov√° P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

20.

Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis.

Brown KL, Flume PA.

J Genet Couns. 2018 Sep;27(5):1049-1054. doi: 10.1007/s10897-018-0220-1. Epub 2018 Feb 10.

PMID:
29429040
21.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

22.

Learning's from the Editors Desk - 2017.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2017 Nov;16(6):645-646. doi: 10.1016/j.jcf.2017.10.001. No abstract available.

PMID:
29150008
23.

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS.

J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.

24.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

25.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

PMID:
28457954
26.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

PMID:
28438499
27.

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?

Flume PA, VanDevanter DR.

Ann Intern Med. 2017 Apr 18;166(8):599-600. doi: 10.7326/M17-0564. Epub 2017 Mar 14. No abstract available.

PMID:
28289748
28.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL.

J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13.

29.

The challenges of maintaining momentum in CF drug development and approval - Commentary.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2017 Mar;16(2):170-171. doi: 10.1016/j.jcf.2017.01.014. Epub 2017 Feb 5. No abstract available.

30.

Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?

Bell SC, Flume PA.

Thorax. 2017 Apr;72(4):297-299. doi: 10.1136/thoraxjnl-2016-209605. Epub 2017 Jan 11. No abstract available.

PMID:
28077615
31.

Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy.

Elborn JS, Davies J, Mall MA, Flume PA, Plant B.

J Cyst Fibros. 2017 Jan;16(1):163-164. doi: 10.1016/j.jcf.2016.11.009. Epub 2016 Dec 13.

32.

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ Jr.

Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823. doi: 10.1164/rccm.201604-0700OC.

33.

Bronchodilators in cystic fibrosis: a critical analysis.

Barry PJ, Flume PA.

Expert Rev Respir Med. 2017 Jan;11(1):13-20. doi: 10.1080/17476348.2017.1246358. Epub 2016 Oct 27. Review.

PMID:
27718752
34.

Efficacy measures for clinical trials: A review series.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2016 Jul;15(4):415. doi: 10.1016/j.jcf.2016.06.002. Epub 2016 Jun 15. No abstract available.

35.

Adults with cystic fibrosis in Portugal: A first step towards improvement.

Raja TH, Flume PA.

Rev Port Pneumol (2006). 2016 May-Jun;22(3):139-40. doi: 10.1016/j.rppnen.2016.05.001. No abstract available.

36.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW.

J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001. Epub 2016 May 24.

37.

Corrigendum to "Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study" [J Cyst Fibros (2015) 632-638].

Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA.

J Cyst Fibros. 2016 Sep;15(5):e54-e55. doi: 10.1016/j.jcf.2016.04.010. Epub 2016 May 17. No abstract available.

38.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

VanDevanter DR, Flume PA, Morris N, Konstan MW.

J Cyst Fibros. 2016 Nov;15(6):783-790. doi: 10.1016/j.jcf.2016.04.005. Epub 2016 Apr 29.

39.
40.

Aerosolized Antibiotics for Patients with Bronchiectasis.

Nadig TR, Flume PA.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):808-10. doi: 10.1164/rccm.201507-1449LE. No abstract available.

PMID:
27035784
41.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR.

J Cyst Fibros. 2016 Sep;15(5):634-40. doi: 10.1016/j.jcf.2016.01.005. Epub 2016 Feb 28.

42.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

43.

The role of 2,4-dihydroxyquinoline (DHQ) in Pseudomonas aeruginosa pathogenicity.

Gruber JD, Chen W, Parnham S, Beauchesne K, Moeller P, Flume PA, Zhang YM.

PeerJ. 2016 Jan 7;4:e1495. doi: 10.7717/peerj.1495. eCollection 2016.

44.

One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.

Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G.

Pediatr Pulmonol. 2016 Apr;51(4):372-8. doi: 10.1002/ppul.23358. Epub 2015 Dec 27.

PMID:
26709158
45.

Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ.

J Pediatr. 2015 Nov;167(5):1081-8.e1. doi: 10.1016/j.jpeds.2015.07.044. Epub 2015 Sep 2.

46.

Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH.

J Cyst Fibros. 2016 Mar;15(2):227-33. doi: 10.1016/j.jcf.2015.07.009. Epub 2015 Aug 28.

47.

Optimising inhaled mannitol for cystic fibrosis in an adult population.

Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM.

Breathe (Sheff). 2015 Mar;11(1):39-48. doi: 10.1183/20734735.021414. Review.

48.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.

49.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

50.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

Supplemental Content

Loading ...
Support Center